Coherus says U.S. Patent Office to review AbbVie's Humira

May 17 (Reuters) - Coherus BioSciences Inc said on

Tuesday the U.S. Patent and Trademark office had agreed to

review its petition to make a copy of AbbVie Inc's

top-selling artritis drug Humira.

Read more